Description General description A cell-permeable, orally active NSAID (nonsteroidal antiinflammatory drug) that blocks cellular Cox pathway PGE2 (prostaglandin E2) production by inhibiting COX-1 and mPGES-1 (microsomal PGE2 synthase-1), but not COX-2, activity (IC50 = 8, 2, and 58 µM, respectively), as well as suppresses cellular 5-LO (5-Lypoxygenase; Cat. No. 437996) pathway activation by inhibiting FLAP (5-LO-activating protein), rather than 5-LO, activity (<10% by 1 µM MK-886). Unlike NSAIDs (nonsteroidal antiinflammatory drugs) that target only COX pathway, MK-886 does not cause gastrointestinal damages when applied in vivo. A cell-permeable, orally active NSAID (nonsteroidal antiinflammatory drug) that blocks cellular Cox pathway PGE2 (prostaglandin E2) production by inhibiting COX-1 and mPGES-1 (microsomal PGE2 synthase-1), but not COX-2, activity (IC50 = 8, 2, and 58 µM, respectively), as well as suppresses cellular 5-LO (5-Lypoxygenase; Cat. No. 437996) pathway activation by inhibiting FLAP (5-LO-activating protein), rather than 5-LO, activity (<10% by 1 µM MK-886). Unlike NSAIDs (nonsteroidal antiinflammatory drugs) that target only COX pathway, MK-886 does not cause gastrointestinal damages when applied in vivo. Packaging 5 mg in Plastic ampoule Biochem/physiol Actions Cell permeable: yes Primary Target leukotreine biosybthesis Product does not compete with ATP. Reversible: no Warning Toxicity: Standard Handling (A) Other Notes Koeberle, A., et al. 2009. Eur. J. Pharmacol.608, 84. Koeberle, A., et al. 2008. J. Pharmacol. Exp. Ther.326, 975. Fisher, L., et al. 2007. Br. J. Pharmacol.152, 471. Ford-Hutchinson, A.W., et al. 1993. Can. J. Physiol. Pharmacol. 71, 806. Ford-Hutchinson, A.W. 1991. Trends Pharmacol.12, 68. Dixon, R.A., et al. 1990. Nature 343, 282. Rouzer, C.A., et al. 1990. J. Biol. Chem.265, 1436.